PPARG and thyroid gland carcinoma: Cyclin D1 isknown to be overexpressed in human thyroid carcinomas[34] and in vitro addition of aPPARγ agonist to human ATC cell linessuppresses cyclin D1 levels [12], confirming thatthis effect is related to alterations in PPARγ rather than TRβ.